SUPINDER RANDHAWA: Open Payments
NPI 1821474230 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,909 in 93 payments from 19 companies in 2025. Trend: 2023 $1,917 · 2024 $2,307 · 2025 $1,909
Food & beverage: $1,909
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 10 | $317 |
| ABBVIE INC. | 14 | $226 |
| Incyte Corporation | 8 | $197 |
| E.R. Squibb & Sons, L.L.C. | 11 | $188 |
| Regeneron Healthcare Solutions, Inc. | 6 | $157 |
| Galderma Laboratories, L.P. | 9 | $153 |
| Lilly USA, LLC | 9 | $129 |
| LEO Pharma Inc. | 6 | $117 |
| Novartis Pharmaceuticals Corporation | 4 | $103 |
| REVANCE THERAPEUTICS, INC. | 2 | $64 |
Products named: DUPIXENT, OPZELURA, Sotyktu, NEMLUVIO, TALTZ, RINVOQ, ADBRY, SKYRIZI.
Industry payments across CA — which companies pay providers there.
